98%
921
2 minutes
20
Purpose: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH (HGNC:3700). This paper quantitatively weights the phenotypic context (PP4/PS4) of such very rare variants in FH.
Methods: We collated clinical diagnostic testing data on germline FH variants from 387 individuals with HLRCC and 1,780 individuals with renal cancer, and compared the frequency of 'very rare' variants in each phenotypic cohort against 562,295 population controls. We generated pan-gene very rare variant likelihood ratios (PG-VRV-LRs), and domain-specific likelihood ratios for missense variants (DS-VRMV-LR) using spatial clustering analysis, and log likelihood ratios (LLRs) as applicable within the updated ACMG/AMP Variant Classification Framework.
Results: For HLRCC, the PG-VRV-LR was estimated to be 2,669.4 (95% CI: 1,843.4-3,881.2, LLR 10.77) for truncating variants and 214.7 (185.0-246.9, LLR 7.33) for missense variants. For renal cancer, the PG-VRV-LR was 95.5 (48.9-183.0, LLR 6.23) for truncating variants and 5.8 (3.5-9.3, LLR 2.39) for missense variants. Clustering analysis in HLRCC cases revealed three 'hotspot' regions wherein the DS-VRMV-LR increased to 1226.9.
Conclusion: These data provide quantitative measures for very rare missense and truncating variants in FH, which reflect the differing phenotypic specificity of HLRCC and renal cancer, and may be applicable in clinical variant classification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.gim.2025.101565 | DOI Listing |
J Am Soc Nephrol
September 2025
AP-HP, Nephrology Department, European Georges Pompidou Hospital, Paris, France.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFRadiol Med
September 2025
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.
View Article and Find Full Text PDFRSC Med Chem
August 2025
Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome Rome Italy
The NRF2/KEAP1 signaling pathway regulates the gene expression of numerous cytoprotective and detoxifying enzymes and is therefore essential for maintaining cellular redox homeostasis. Despite the increasing knowledge of NRF2 signaling complexity, dimethyl fumarate remains the sole NRF2-targeting therapy in clinical practice, used for multiple sclerosis. Ongoing research exploring the role of NRF2 in cancer, neurodegeneration, diabetes, and cardiovascular, renal, and liver diseases holds significant promise for future therapeutic innovation.
View Article and Find Full Text PDFEur Urol Open Sci
October 2025
Department of Urology, CHU Rennes, Rennes, France.
Background And Objective: Surgery of renal cell cancer (RCC) with a caval thrombus (CT) is associated with significant morbidity, particularly regarding thromboembolic complications. There are no data or recommendations regarding the potential benefit of preoperative anticoagulants. We aimed to assess the usefulness of preoperative anticoagulation regarding surgical outcomes and thromboembolic events in patients undergoing nephrectomy with inferior vena cava thrombectomy.
View Article and Find Full Text PDF